To understand the role of the CYP4/20- HETE/GPR75 axis in the progression of MASLD, we analyzed the production of 20-HETE in the liver of patients with steatosis, steatohepatitis, cirrhosis, or fatty liver-induced hepatocellular carcinoma. Here, GPR75 is linked to metabolic dysfunction-associated steatotic liver disease.